melanoma Archives -

Merck gets on board with Moderna cancer vaccine in $250m deal

Phil Taylor cancer vaccine, immuno-oncology, melanoma, Merck & Co, Moderna, Oncology, partnering, personalised medicine 0 Comment

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised

Merck gets on board with Moderna cancer vaccine in $250m deal

https://pharmaphorum.com/news/merck-gets-on-board-with-moderna-cancer-vaccine-in-250m-deal/

Market Access/ News/ News/ News/ Oncology

Routine NHS access to Ibrance assured with new NICE guidance

Phil Taylor breast cancer, HEOR, Ibrance, Keytruda, melanoma, Merck & Co, NHS, NICE, Oncology, Pfizer, renal cell carcinoma 0 Comment

Thousands of patients with a particular form of breast cancer in England and Wales can be confident they

Routine NHS access to Ibrance assured with new NICE guidance

https://pharmaphorum.com/news/routine-nhs-access-to-ibrance-assured-with-new-nice-guidance/

News/ News/ Oncology

Opdivo set to take on Keytruda in adjuvant melanoma

Phil Taylor adjuvant, Bristol-Myers Squibb, Keytruda, melanoma, Merck & Co, Opdivo 0 Comment

Bristol-Myers Squibb’s Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending

Opdivo set to take on Keytruda in adjuvant melanoma

https://pharmaphorum.com/news/opdivo-set-to-take-on-keytruda-in-adjuvant-melanoma/

Insights/ Oncology/ Views and analysis

A history of blood cancer treatment

Eloise McLennan A history of..., blood cancer, bone marrow transplant, breakthroughs, CAR-T therapies, cell therapies, chemotherapy, cord blood, immunology, leukaemia, lymphoma, melanoma, Non-Hodgkins Lymphoma 0 Comment

Despite being one of the most common forms of cancer, awareness of blood cancer pales in comparison to

A history of blood cancer treatment

https://pharmaphorum.com/oncology/a-history-of-blood-cancer-treatment/

News/ News/ Oncology

ESMO: TIL therapy improves on Yervoy in melanoma trial

Phil Taylor cell therapy, ESMO 2022, immuno-oncology, melanoma, Oncology, tumour-infiltrating lymphocytes 0 Comment

A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at

ESMO: TIL therapy improves on Yervoy in melanoma trial

https://pharmaphorum.com/news/esmo-til-therapy-improves-on-yervoy-in-melanoma-trial/

News/ News/ News/ Oncology/ Sales and Marketing

Opdualag off to a flying start, says BMS CEO

Phil Taylor Bristol-Myers Squibb, Financial, immuno-oncology, melanoma, Oncology, Opdualag 0 Comment

Bristol-Myers Squibb’s new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few

Opdualag off to a flying start, says BMS CEO

https://pharmaphorum.com/news/opdualag-off-to-a-flying-start-says-bms-ceo/

News/ News/ News/ Oncology/ R&D

Regeneron seeks CheckMate in immuno-oncology play

Phil Taylor CheckMate Pharma, head and neck cancer, immuno-oncology, M&A, melanoma, Oncology, Regeneron, toll-like receptor agonist, vidutolimod 0 Comment

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy

Regeneron seeks CheckMate in immuno-oncology play

https://pharmaphorum.com/news/regeneron-seeks-checkmate-in-immuno-oncology-play/

News/ News/ Oncology

Sour taste for Nektar as bempegaldesleukin flunks ph3 test

Phil Taylor Bristol-Myers Squibb, immuno-oncology, melanoma, Nektar Therapeutics, Oncology 0 Comment

Four years ago, Bristol-Myers Squibb paid $1.85 billion upfront to claim rights to Nektar’s bempegaldesleukin, setting it up

Sour taste for Nektar as bempegaldesleukin flunks ph3 test

https://pharmaphorum.com/news/sour-taste-for-nektar-as-bempegaldesleukin-flunks-ph3-test/

Market Access/ News/ News

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

Phil Taylor adjuvant, HEOR, melanoma, Merck & Co, NHS, NICE 0 Comment

After three years of availability via the Cancer Drugs Fund (CDF), MSD’s checkpoint inhibitor Keytruda has now been

NICE gives Keytruda parity with Opdivo for adjuvant melanoma

https://pharmaphorum.com/news/after-stint-on-cdf-nice-makes-keytruda-routine-for-adjuvant-melanoma/

Trending

melanoma

Login